Report: Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal – Benzinga

Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc. (NASDAQ: IMMU) for a price tag exceeding $20 billion.

Per the Wall Street Journal, Immunomedics — a biotech known for breast-cancer treatment Trodelvy — was initially a partner of Gilead before takeover talks began. 

Terms are expected to be announced Monday. 

Immunomedics, whose valuation hovers $10 billion, is just the latest in a series of deals Gilead made in 2020.

In June, Foster City, California-based Gilead acquired a 49.9% stake in cancer drug developer Pionyr Immunotherapeutics for $275 million. Before that, it spent $4.9 billion for Forty Seven Inc., a company that makes blood cancer treatments.

Gilead closed Friday, Sept. 11 at $65.58 a share, while Immunomedics shares closed at $41.93.

© 2020 Benzinga does not provide investment advice. All rights reserved.


READ  Market Wrap: Bitcoin Pushes to $11,450, DeFi Value Locked Now at $4B - Nasdaq


Please enter your comment!
Please enter your name here